Desmoglein 3 as a prognostic indicator in lung cancer

被引：0
|
作者：
Fukuoka, J
Dracheva, T
Shih, J
Hewitt, S
Shilo, K
Franks, T
Travis, W
Jen, J
机构：
[1] Toyama Med & Pharmaceut Univ Hosp, Dept Pathol, Toyama, Japan
[2] NCI, Lab Populat Genet, Toyama, Japan
[3] NCI, Biometr Res Branch, Toyama, Japan
[4] AFIP, Dept Pulm & Mediastinal Pathol, Toyama, Japan
[5] NCI, Lab Pathol, Toyama, Japan
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, Toyama, Japan
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80341-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [31] Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
    Barber, Alison G.
    Castillo-Martin, Mireia
    Bonal, Dennis M.
    Rybicki, Benjamin A.
    Christiano, Angela M.
    Cordon-Cardo, Carlos
    PLOS ONE, 2014, 9 (06):
  • [32] Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
    Yan, Xuebing
    Wang, Jiaxin
    Mao, Jingxian
    Wang, Ying
    Wang, Xiangjun
    Yang, Mengxue
    Qiao, Hong
    FRONTIERS IN NUTRITION, 2023, 10
  • [33] &x264;-glutamyl hydroxymethyl rhodamine green fluorescence as a prognostic indicator for lung cancer
    Kawashima, Shun
    Yoshioka, Takafusa
    Hino, Haruaki
    Kitano, Kentaro
    Nagayama, Kazuhiro
    Sato, Masaaki
    Kojima, Ryosuke
    Kamiya, Mako
    Urano, Yasuteru
    Nakajima, Jun
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2020, 68 (12) : 1418 - 1424
  • [34] Immunophenotyping in Non-Small Cell Lung Cancer as an indicator for prognostic Information and treatment Decisions
    Stump, J.
    Tufman, A.
    Reu, S.
    Berger, F.
    Ballesteros-Merino, C.
    Neuberger, M.
    Feng, Z.
    Hatz, R.
    Lindner, M.
    Sanbom, R. E.
    Handy, J.
    Fox, B. A.
    Bifulco, C. B. Carlo B.
    Huber, R. M.
    Winter, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 122
  • [35] Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer
    Aoe, K
    Hiraki, A
    Maeda, T
    Katayama, H
    Fujiwara, K
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    INTERNAL MEDICINE, 2005, 44 (08) : 800 - 804
  • [36] CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer
    Dai, Fang
    Duan, Yu-lian
    Feng, Qiang
    Song, Shu-Ling
    Yang, Ju-Lun
    Lv, Tao
    JOURNAL OF CANCER, 2024, 15 (08): : 2373 - 2379
  • [37] Pretreatment hemoglobin level is a prognostic indicator in patients with non-small-cell lung cancer
    Lu Shun
    Gu Lin-Ping
    Yu Yong-Feng
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S454 - S454
  • [38] EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Dubey, Sarita
    Stephenson, Patricia
    Levy, Donna E.
    Miller, Judith A.
    Keller, Steven M.
    Schiller, Joan H.
    Johnson, David H.
    Kolesar, Jill M.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (05) : 406 - 412
  • [39] Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer
    Marchetti, A
    Bertacca, G
    Buttitta, F
    Chella, A
    Quattrocolo, G
    Angeletti, CA
    Bevilacqua, G
    CLINICAL CANCER RESEARCH, 1999, 5 (08) : 2077 - 2081
  • [40] Exclusive liver invasion as prognostic indicator in T3 gallbladder cancer
    Lee, Woohyung
    Shin, Arum
    Song, Ki Byung
    Lee, Jae Hoon
    Hwang, Dae Wook
    Kim, Song Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 631 - 631
12345